Bioequivalence of Eye Drops and Spray Administration of Vigamox
NCT ID: NCT00666042
Last Updated: 2012-01-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
16 participants
INTERVENTIONAL
2009-02-28
2009-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Using Device Delivering Ophthalmic Solution in a Spray Form Instead of Eye Drops
NCT00565630
Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections
NCT00690313
Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients
NCT01859702
Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification
NCT01296191
A Comparison of Prophylactic Antibacterial Efficacy of Besivance vs. VIGAMOX Prior to Cataract Surgery
NCT01296542
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Vigamox delivered as spray
Vigamox - administration in spray form
Vigamox will be administered in a spray form
B
Patients will receive the commercially available Vigamox drops
Vigamox eye drops
Vigamox eye drops
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vigamox - administration in spray form
Vigamox will be administered in a spray form
Vigamox eye drops
Vigamox eye drops
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Advanced Ophthalmic Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tel Aviv Medical Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adi Michaeli, MD
Role: PRINCIPAL_INVESTIGATOR
TAMC, Tel Aviv, Israel
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dept. of Ophthalmology, TAMC
Tel Aviv, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
different administrations
Identifier Type: -
Identifier Source: secondary_id
Eye drops vs. spray
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.